Eyal Mishani

4.9k total citations · 1 hit paper
87 papers, 3.8k citations indexed

About

Eyal Mishani is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Eyal Mishani has authored 87 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Radiology, Nuclear Medicine and Imaging, 35 papers in Pulmonary and Respiratory Medicine and 25 papers in Oncology. Recurrent topics in Eyal Mishani's work include Radiopharmaceutical Chemistry and Applications (27 papers), Medical Imaging Techniques and Applications (21 papers) and Lung Cancer Treatments and Mutations (21 papers). Eyal Mishani is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (27 papers), Medical Imaging Techniques and Applications (21 papers) and Lung Cancer Treatments and Mutations (21 papers). Eyal Mishani collaborates with scholars based in Israel, United States and United Kingdom. Eyal Mishani's co-authors include Einat Even‐Sapir, Ur Metser, Alexander Levitzki, Hedva Lerman, Gennady Lievshitz, Ilan Leibovitch, Galith Abourbeh, Shlomo Rozen, Roland Chisin and Gideon Flusser and has published in prestigious journals such as Journal of the American Chemical Society, Annual Review of Biochemistry and ACS Nano.

In The Last Decade

Eyal Mishani

87 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.

2006 589 citations Einat Even‐Sapir, Eyal Mishani et al. profile →

Peers

Countries citing papers authored by Eyal Mishani

Since Specialization

Citations

This map shows the geographic impact of Eyal Mishani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eyal Mishani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eyal Mishani more than expected).

Fields of papers citing papers by Eyal Mishani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eyal Mishani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eyal Mishani. The network helps show where Eyal Mishani may publish in the future.

Co-authorship network of co-authors of Eyal Mishani

This figure shows the co-authorship network connecting the top 25 collaborators of Eyal Mishani. A scholar is included among the top collaborators of Eyal Mishani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eyal Mishani. Eyal Mishani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	False Positive Findings of [18F]PSMA-1007 PET/CT in Patients After Radical Prostatectomy with Undetectable Serum PSA Levels 2022 ·Frontiers in Surgery ·Marina Orevi, Simona Ben‐Haim, Galith Abourbeh, (unknown), Eyal Mishani, Vladimir Yutkin, Ofer N. Gofrit	11
2	Head-to-Head Comparison of ⁶⁸Ga-PSMA-11 with ¹⁸F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard 2019 ·Journal of Nuclear Medicine ·Jonathan Kuten, (unknown), Ziv Savin, Ofer Shamni, Gilad Gitstein, Dov Hershkovitz, Nicola J. Mabjeesh, Ofer Yossepowitch, Eyal Mishani, Einat Even‐Sapir	156
3	Development of a Fluorinated Analogue of Erlotinib for PET Imaging of EGFR Mutation–Positive NSCLC 2018 ·Molecular Imaging and Biology ·Ofer Shamni, (unknown), (unknown), Eyal Mishani, Galith Abourbeh	9
4	A multi species evaluation of the radiation dosimetry of [ 11 C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor 2017 ·Nuclear Medicine and Biology ·(unknown), Søren B. Hansen, Galith Abourbeh, Maqsood Yaqub, Idris Bahce, Daniel Holden, Yiyun Huang, Nabeel Nabulsi, Joseph N. Contessa, Eyal Mishani, Adriaan A. Lammertsma, Evan D. Morris	6
5	Comprehensive Auditing in Nuclear Medicine Through the International Atomic Energy Agency Quality Management Audits in Nuclear Medicine Program. Part 2: Analysis of Results 2017 ·Seminars in Nuclear Medicine ·Maurizio Dondi, Leonel Torres, Mario Marengo, Teresa Massardo, Eyal Mishani, A Ellmann, (unknown), Angelika Bischof Delaloye, (unknown), (unknown), (unknown), Diana Páez, Thomas N.B. Pascual	8
6	PET Molecular Imaging of Angiogenesis with a Multiple Tyrosine Kinase Receptor-Targeted Agent in a Rat Model of Myocardial Infarction 2014 ·Molecular Imaging and Biology ·(unknown), Galith Abourbeh, (unknown), Eyal Mishani, Orit Jacobson	6
7	Localization of Parathyroid Adenoma by 11C-Choline PET/CT 2014 ·Clinical Nuclear Medicine ·Marina Orevi, Nanette Freedman, Eyal Mishani, Moshe Bocher, Orit Jacobson, Yodphat Krausz	61
8	Gating, enhanced gating, and beyond: information utilization strategies for motion management, applied to preclinical PET 2013 ·EJNMMI Research ·Adam Kesner, Galith Abourbeh, Eyal Mishani, Roland Chisin, Sagi Tshori, Nanette Freedman	19
9	Growth-limiting role of endothelial cells in endoderm development 2011 ·Developmental Biology ·Fredrik Wolfhagen Sand, Andreas Hörnblad, Jenny K. Johansson, Christina E. Lorén, Josefina Edsbagge, Anders Ståhlberg, Judith Magenheim, Ohad Ilovich, Eyal Mishani, Yuval Dor, Ulf Ahlgren, Henrik Semb	34
10	Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET 2010 ·Molecular Imaging and Biology ·Maria A. Pantaleo, Eyal Mishani, Cristina Nanni, Lorena Landuzzi, Stefano Boschi, Giordano Nicoletti, (unknown), Paola Paterini, Pier Paolo Piccaluga, Filippo Lodi, Pier‐Luigi Lollini, Stefano Fanti, Guido Biasco	16
11	Strategies for Molecular Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase in Cancer 2009 ·Journal of Nuclear Medicine ·Eyal Mishani, Aviv Hagooly	44
12	Mice Deficient in Ribosomal Protein S6 Phosphorylation Suffer from Muscle Weakness that Reflects a Growth Defect and Energy Deficit 2009 ·PLoS ONE ·(unknown), Maximiliano J. Katz, Avigail Dreazen, Yuval Gielchinsky, Ann Saada, Nanette Freedman, Eyal Mishani, Gabriel Zimmerman, Judith Kasir, Oded Meyuhas	86
13	Monitoring of tumor response to therapy by 18F-ML-10, a novel small-molecule PET tracer for apoptosis: From preclinical to clinical studies 2008 ·Clinical Cancer Research ·Anat Shirvan, Hagit Grimberg, Galit Levin, Avi Cohen, Ayelet Reshef, (unknown), Aaron M. Allen, Eyal Fenig, Adam Steinmetz, David Groshar, (unknown), Yulia Kundel, Eyal Mishani, Ilan Ziv	1
14	Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter 2008 ·Bioorganic & Medicinal Chemistry ·(unknown), Winnie Deuther‐Conrad, Matthias Scheunemann, Jörg Steinbach, Peter Brust, Eyal Mishani	8
15	The effect of the [F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety—An EGFR putative irreversible inhibitor 2007 ·Applied Radiation and Isotopes ·(unknown), (unknown), (unknown), Galith Abourbeh, Alexander Levitzki, Eyal Mishani	25
16	IFN-γ Acts on T Cells to Induce NK Cell Mobilization and Accumulation in Target Organs 2006 ·The Journal of Immunology ·Ori Wald, Ido D. Weiss, Hanna Wald, Hadas Shoham, (unknown), Katia Beider, Eithan Galun, Lola Weiss, Liat Flaishon, Idit Shachar, Arnon Nagler, Bao Lu, Craig Gérard, Ji‐Liang Gao, Eyal Mishani, Joshua Μ. Farber, Amnon Peled	77
17	Chiral dimethylamine flutamide derivatives—modeling, synthesis, androgen receptor affinities and carbon-11 labeling 2006 ·Nuclear Medicine and Biology ·Orit Jacobson, (unknown), Kathryn E. Carlson, Sharona Elgavish, Michael Gozin, Einat Even‐Sapir, (unknown), Mordechai Gutman, Roland Chisin, John A. Katzenellenbogen, Eyal Mishani	11
18	Backbone metal cyclization: Novel 99mTc labeled GnRH analog as potential SPECT molecular imaging agent in cancer 2004 ·Nuclear Medicine and Biology ·(unknown), (unknown), (unknown), Nurit Ben‐Aroya, Yitzhak Koch, Eyal Mishani, Mati Fridkin, Chaim Gilon	36
19	Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors 2004 ·Nuclear Medicine and Biology ·Eyal Mishani, Galith Abourbeh, (unknown), Orit Jacobson, (unknown), (unknown), Alexander Levitzki, (unknown)	63
20	Application of a novel phenylpiperazine formation reaction to the radiosynthesis of a model fluorine-18-labeled radiopharmaceutical (18FTFMPP) 1997 ·Nuclear Medicine and Biology ·Eyal Mishani, (unknown), Carmen S. Dence, Timothy J. McCarthy, Michael J. Welch	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact